Xtant Medical Holdings, Inc. (XTNT) is a publicly traded Healthcare sector company. As of May 21, 2026, XTNT trades at $0.46 with a market cap of $63.96M and a P/E ratio of 11.70. XTNT moved +1.33% today. Year to date, XTNT is -34.49%; over the trailing twelve months it is -33.75%. Its 52-week range spans $0.33 to $0.95. Analyst consensus is strong buy with an average price target of $1.25. Rallies surfaces XTNT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Xtant Medical Lifts 2026 Revenue Guidance to $101–$105M, Secures HEMOBLAST Distribution: Xtant Medical generated $20.9 million in Q1 revenue, down from $32.9 million due to asset sales and nonrecurring license income, while reducing indebtedness by $13.3 million. The company raised full-year 2026 revenue guidance to $101–$105 million, reflecting additional sales of Dilon’s HEMOBLAST® Bellows and product launches.
| Metric | Value |
|---|---|
| Price | $0.46 |
| Market Cap | $63.96M |
| P/E Ratio | 11.70 |
| EPS | $0.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.95 |
| 52-Week Low | $0.33 |
| Volume | 212 |
| Avg Volume | 0 |
| Revenue (TTM) | $133.93M |
| Net Income | $4.97M |
| Gross Margin | 62.92% |
3 analysts cover XTNT: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $1.25.